Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 2Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Diseases 1Prostate Cancer Metastatic 1Pheochromocytoma 1Paraganglioma 1Oligometastatic Prostate Cancer (OMPC) 1Neoplasm Metastasis 1Metastatic Neuroendocrine Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Lung Neoplasms 1Digestive System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms 1Biochemically Recurrent Prostate Carcinoma 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Pluvicto 1Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration Resistant Prostate Cancer (mCRPC) × Lutetium-177 × 1 year × Clear all
NCT06894511 2026-05-01

PSMAndARPI

Novartis

Phase 2 Active not recruiting
7 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡